Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 24, Issue 25, p.4143-9 (2006)

Keywords:

Adult, Aged, Antibodies, Monoclonal, Antigens, CD20, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Female, Follow-Up Studies, Humans, Lymphoma, Follicular, Male, Middle Aged, Polymerase Chain Reaction, Prednisone, Radioimmunotherapy, Survival Analysis, Treatment Outcome, United States, Vincristine

Abstract:

Advanced follicular lymphoma (FL) is incurable with conventional chemotherapy and radiotherapy, and optimal front-line management is controversial. This study was performed to determine the efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy followed by tositumomab/iodine I-131 tositumomab.